MarginsXMarginsX
Home › Markets › Health Care › MRNA

Moderna Inc. (MRNA)

MRNA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$215.27
-3.63% on the day
Market cap
$87.1B
Large cap
Revenue · 2025
$1.9B
-39.9% on 2024
Net income · 2025
-$2.8B
-145.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/0001682852-26-000033-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMRNA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001682852
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.9B
Net income-$2.8B
Operating income-$3.1B
Net margin-145.2%
Operating margin-158.1%
Revenue growth-39.9%
Cash$2.6B
Total assets$12.3B
P/E (computed)Net income was not positive
P/S (computed)44.8×

Warning signs

Cash runway
8.0 months
$1.2B cash at September 30, 2026
Share count, 1 year
+3.6%
2025-10-31 to 2026-10-30 · +6.1% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
-$64.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$1.2B cash; operating cash flow -$446.3M a quarter.Report 2026-09-30
Shares outstanding404,620,975 (2026-10-30); 390,679,512 a year earlier; 381,283,996 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $64.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.3B$162.0M-$1.6B$1.2BNo debt tags$2.5B10-Q 2026-11-06
Q2 2026
2026-06-30
$145.0M-$782.0M-$526.0M$1.7B$591.0M$2.2B10-Q 2026-07-31
Q1 2026
2026-03-31
$389.0M-$1.3B-$630.0M$1.9B$590.0M$2.2B10-Q 2026-05-01
Q4 2025
2025-12-31
$678.0M-$826.0M$930.0M$2.6B$590.0M$1.9B10-K 2026-02-20
Q3 2025
2025-09-30
$1.0B-$200.0M-$847.0M$1.1BNo debt tags$2.2B10-Q 2026-11-06
Q2 2025
2025-06-30
$142.0M-$825.0M-$919.0M$1.3BNo debt tags$3.1B10-Q 2026-07-31
Q1 2025
2025-03-31
$108.0M-$971.0M-$1.0B$1.6BNo debt tags$3.2B10-Q 2026-05-01
Q4 2024
2024-12-31
$966.0M-$1.1B$825.0M$1.9B$0$3.2B10-K 2026-02-20

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2023-05-05
Latest annual report10-K2026-02-20
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-16
Latest proxy
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
DEFA14A2026-03-16

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-12.1%
1 month+3.3%
3 months+250.9%
Year to date+657.4%
1 year+794.9%
From 52-week high-17.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ARGXargenx SE$950.95-0.95%$59.0B
BIIBBiogen Inc.$251.65-0.69%$37.2B
GILDGilead Sciences Inc.$167.58-0.30%$207.9B
RVMDRevolution Medicines Inc.$166.87-3.15%$36.1B
AMGNAmgen Inc.$462.32-0.72%$250.1B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
EXELExelixis Inc.$67.10-2.75%$16.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier